Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
Aging Cell · 2023-08 · 22 (8)
DOI: 10.1111/acel.13888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 24.05.2023. Verfasst von Filippo Artoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute for Biology of Ageing (MPI-AGE), Cologne, Germany. Hauptthemen laut MEDLINE: MTOR Inhibitors, Signal Transduction. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council.
Abstract (Originalsprache)
Rapamycin is a macrolide antibiotic that functions as an immunosuppressive and anti‐cancer agent, and displays robust anti‐ageing effects in multiple organisms including humans. Importantly, rapamycin analogues (rapalogs) are of clinical importance against certain cancer types and neurodevelopmental diseases. Although rapamycin is widely perceived as an allosteric inhibitor of mTOR (mechanistic target of rapamycin), the master regulator of cellular and organismal physiology, its specificity has not been thoroughly evaluated so far. In fact, previous studies in cells and in mice hinted that rapamycin may be also acting independently from mTOR to influence various cellular processes. Here, we generated a gene‐edited cell line that expresses a rapamycin‐resistant mTOR mutant (mTOR RR ) and assessed the effects of rapamycin treatment on the transcriptome and proteome of control or mTOR RR ‐expressing cells. Our data reveal a striking specificity of rapamycin towards mTOR, demonstrated by virtually no changes in mRNA or protein levels in rapamycin‐treated mTOR RR cells, even following prolonged drug treatment. Overall, this study provides the first unbiased and conclusive assessment of rapamycin's specificity, with potential implications for ageing research and human therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max Planck Institute for Biology of Ageing (MPI-AGE), Cologne, Germany.
- Cologne Graduate School of Ageing Research (CGA), Cologne, Germany.
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
ORCID-Profile: Filippo Artoni, Constantinos Demetriades
Förderung
- H2020 European Research Council
Zitieren
APA
Artoni, F., Grützmacher, N., & Demetriades, C. (2023). Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor. Aging Cell, 22(8). https://doi.org/10.1111/acel.13888
Vancouver
Artoni F, Grützmacher N, Demetriades C. Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor. Aging Cell. 2023;22(8). doi:10.1111/acel.13888
BibTeX
@article{Artoni2023,
author = {Artoni, Filippo and Grützmacher, Nina and Demetriades, Constantinos},
title = {Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor},
journal = {Aging Cell},
year = {2023},
volume = {22},
number = {8},
doi = {10.1111/acel.13888}
}
EUVIMED